Evidence map›Paper›PMID 39468351›Full record

ArticleEMBO reports2024

Human PC4 supports telomere stability and viability in cells utilizing the alternative lengthening of telomeres mechanism.

Sara Salgado, Patricia L Abreu, Beatriz Moleirinho, Daniela S Guedes, Lee Larcombe, Claus M Azzalin

Erratum issuedAbstract read
In one paragraph

Article in EMBO reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. eLife · 2026
    Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Sara SalgadoGIMM - Gulbenkian Institute for Molecular Medicine, 1649-035, Lisbon, Portugal.ORCID 0000-0003-2050-3185
Patricia L AbreuGIMM - Gulbenkian Institute for Molecular Medicine, 1649-035, Lisbon, Portugal.ORCID 0000-0002-6387-8537
Beatriz MoleirinhoGIMM - Gulbenkian Institute for Molecular Medicine, 1649-035, Lisbon, Portugal.ORCID 0000-0003-3047-658X
Daniela S GuedesGIMM - Gulbenkian Institute for Molecular Medicine, 1649-035, Lisbon, Portugal.ORCID 0000-0003-3757-6006
Lee LarcombeApexomic, Stevenage Bioscience Catalyst, Hertfordshire, SG1 2FX, UK.ORCID 0000-0003-3150-6445
Claus M AzzalinGIMM - Gulbenkian Institute for Molecular Medicine, 1649-035, Lisbon, Portugal. claus.azzalin@gimm.pt.ORCID 0000-0002-9396-1980

Funding

Fundação para a Ciência e a Tecnologia (FCT) 2021.00143.CEECINDFundação para a Ciência e a Tecnologia (FCT) 2022.11369.BDFundação para a Ciência e a Tecnologia (FCT) PTDC/MED-ONC/7864/2020LaCaixa Foundation LCF/PR/HP21/52310016TessellateBio LCF/PR/HP21/52310016
6 · The paper itself

Abstract

Cancer cells with an activated Alternative Lengthening of Telomeres (ALT) mechanism elongate telomeres via homology-directed repair. Sustained telomeric replication stress is an essential trigger of ALT activity; however, it can lead to cell death if not properly restricted. By analyzing publicly available data from genome-wide CRISPR KO screenings, we have identified the multifunctional protein PC4 as a novel factor essential for ALT cell viability. Depletion of PC4 results in rapid ALT cell death, while telomerase-positive cells show minimal effects. PC4 depletion induces replication stress and telomere fragility primarily in ALT cells, and increases ALT activity. PC4 binds to telomeric DNA in cells, and its binding can be enhanced by telomeric replication stress. Finally, a mutant PC4 with partly impaired single stranded DNA binding activity is capable to localize to telomeres and suppress ALT activity and telomeric replication stress. We propose that PC4 supports ALT cell viability, at least partly, by averting telomere dysfunction. Further studies of PC4 interactions at ALT telomeres may hold promise for innovative therapies to eradicate ALT cancers.

Indexed as

Cell SurvivalDNA ReplicationTelomereTelomere HomeostasisCell Line, TumorHumansProtein BindingTelomeraseTelomeraseAlternative Lengthening of TelomeresCancerPC4/Sub1Replications Stress

Identifiers

PMID39468351
PMCPMC11624207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.